1-1 of 1
Clemens H. Mellink
Close
Sort by
Journal Articles

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL

Clinical Trials & Observations
Arnon P. Kater, Sabina Kersting, Yvette van Norden, Julie Dubois, Johan A. Dobber, Clemens H. Mellink, Ludo M. Evers, Fransien Croon-de Boer, John Schreurs, Ellen van der Spek, Hein Visser, Cecile Idink, Shulamiet Wittebol, Mels Hoogendoorn, Sanne H. Tonino, Mehrdad Mobasher, Mark-David Levin
Journal: Blood Advances
Blood Adv (2018) 2 (24): 3566–3571.
https://doi.org/10.1182/bloodadvances.2018019422
Published: 2018
Includes: Supplemental data